BioSpace News Archive

Labcorp, a leading global life sciences company, and AtlantiCare, the largest health care organization in southern New Jersey, announced that they have closed a transaction to expand their long-term strategic relationship.

Evox Therapeutics Ltd, a leading exosome therapeutics company, announced two oral presentations at the International Society for Cell & Gene Therapy 2022 Meeting, May 4 to 7, in San Francisco.

Foghorn® Therapeutics Inc., a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, provided a corporate update in conjunction with the Company’s 10-Q filing for the quarter ended March 31, 2022.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update, and announced its financial results for the first quarter ended March 31, 2022.

Passage Bio, Inc. announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 16, 2022, to report its first quarter 2022 financial results and discuss recent business highlights.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the first quarter ended March 31, 2022, and noted key upcoming anticipated milestones.

TELA Bio, Inc. announced that the Company will participate in the 2022 H.C. Wainwright Annual Global Investment Conference on May 24th, 2022.

Akari Therapeutics, plc (Nasdaq: AKTX), a late-stage biotechnology company focused on the development of advanced therapies for autoimmune and inflammatory diseases, presented positive results from two preclinical studies of its lead asset, investigational nomacopan, in diseases of the eye at the Association of Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the first quarter ended March 31, 2022 and provided an update on key strategic initiatives.

Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Monday, May 16, 2022 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2022, and to provide a business overview.